Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pAKK_LWHK0003 in MASLD
NCT07488975Phase 1Active, not recruiting
- Sponsor
- Leeuwenhoek Laboratories Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised trial of Pasteurized Akkermansia muciniphila LWHK0003 in metabolic dysfunction-associated steatotic liver disease (MASLD) (4 arms), sponsored by Leeuwenhoek Laboratories Co., Ltd. Primary endpoints: Liver steatosis up to 52 weeks, Liver fibrosis up to 52 weeks and 2 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
Pasteurized Akkermansia muciniphila LWHK0003
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07488975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07488975.